Expression of Coxsackie Adenovirus Receptor in Cutaneous T-Cell Lymphoma: Potential for Skin Targeted Gene Therapy.

Cutaneous T-cell lymphoma (CTCL) represents a spectrum of diseases characterized by the accumulation of clonal lymphocytes in the skin. It has been well established that primary cutaneous lymphomas of T-cell lineage have shown ALK protein expression. Furthermore, we have previously shown that ALK-ALCL cell lines highly express the coxsackie-adenovirus receptor (CAR), primary receptor for recombinant wild type-fiber adenovirus-derived vectors for gene therapy. Since skin-directed therapies are the preferred first-line treatment the presence of CAR in CTCL may be helpful in developing therapeutic modalities such gene or targeted molecular therapy. By using ALK-immunostaining, we analyzed retrospectively a series of human tissue primarily diagnosed as CTCL [5 mycosis fungoides (MF), 4 (ALCL)] or peripheral T cell lymphoma (1 PTCL) in order to establish the level of CAR expression in primary CTCL tissue. Fluorescence in situ hybridization (FISH) analyses were also performed on these cases using a locus specific DNA probe for the ALK/p2 locus. We used ALK identification because at the time when the primary diagnosis was placed, the samples were not tested for ALK expression. Patients ranged in age from 32–73 years old with a median age of 58. Normal skin biopsies from 8 patients were used as controls. The results of our analysis are illustrated in Table 1.

In this study, we show that the immunostaining of CAR in combination with classic ALK-immuno or ALK-FISH is feasible and helps in identifying CTCL cases candidate for skin targeted adenoviral-mediated gene therapy.